Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Acrivon Therapeutics, Inc. (ACRV) had Normalized Pre-Tax Income of $-19.68M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-19.68M |
|
-- |
|
-- |
|
$21.66M |
|
$-21.66M |
|
$1.98M |
|
$-19.68M |
|
|
Normalized Pre-Tax Income |
$-19.68M |
$-19.68M |
|
$-19.68M |
|
$-19.68M |
|
$-19.68M |
|
$-21.66M |
|
$-21.71M |
|
38.35M |
|
38.35M |
|
$-0.51 |
|
$-0.51 |
|
| Balance Sheet Financials | |
$151.33M |
|
$4.68M |
|
$25.02M |
|
$176.35M |
|
$13.55M |
|
-- |
|
$2.41M |
|
$15.96M |
|
$160.39M |
|
$160.39M |
|
$160.39M |
|
31.35M |
|
| Cash Flow Statement Financials | |
$-19.54M |
|
$19.21M |
|
$-0.34M |
|
$40.02M |
|
$39.35M |
|
$-0.66M |
|
$3.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.17 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-19.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.27% |
|
-12.27% |
|
-11.16% |
|
-12.27% |
|
$5.12 |
|
$-0.51 |
|
$-0.51 |
|